Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings

Journal of Infectious Diseases

Volumn 202, Issue 12, 2010, Pages 1789-1799

  Bruni, Laia ^a   Diaz, Mireia ^a   Castellsagué, Xavier ^a,b   Ferrer, Elena ^a   Bosch, F Xavier ^a   De Sanjosé, Silvia ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS LOAD; WART VIRUS;

ADOLESCENT; ADULT; AFRICA; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; AMERICAS; ASIA; CERVIX UTERI; DNA, VIRAL; EUROPE; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PANDEMICS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; YOUNG ADULT;

EID: 78650324137     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/657321     Document Type: Article

References (41)

1. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1-24.
2. European Cervical Cancer Association. HPV vaccination across Europe. http://www.ecca.info/fileadmin/user-upload/HPV-Vaccination/ECCA-HPV-Vaccination- April-2009.pdf. Published 2009. Accessed 31 May 2009.
3. Jagu S, Karanam B, Gambhira R, et al. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst 2009; 101:782-792.
4. Merck. Broad spectrum HPV (human papillomavirus) vaccine study in 16-to 26-year-old women (V503-001). http://clinicaltrials.gov/show/NCT00543543. Accessed 2 November 2009.
5. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360:1385-1394.
6. Muñoz N, Franco EL, Herrero R, et al. Recommendations for cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008; 26(suppl 11):L96-L107.
7. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7: 453-459.
8. World Health Organization and Institut Català d'Oncologia (ICO). WHO/ICO Information Centre on HPV and Cervical Cancer. http://www.who.int/ hpvcentre/en/. Accessed 16 March 2009.
9. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366:991-998.
10. Womack SD, Chirenje ZM, Gaffikin L, et al. HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer 2000; 85:206-210.
11. Bohning D, Dietz E, Schlattmann P. Recent developments in computerassisted analysis of mixtures. Biometrics 1998; 54:525-536.
12. United Nations Statistics Division. Standard country and area codes classifications (M49). http://unstats.un.org/unsd/methods/m49/m49regin.htm. Accessed 16 March 2009.
13. Population Division, Department of Economic and Social Affairs, United Nations Secretariat. World population prospects: the 2005 revision. New York, NY: United Nations. 2005.
14. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Fiveyear experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 2009; 113:595-600.
15. Zhao C, Elishaev E, Yuan KH, Yu J, Marshall Austin R. Very low human papillomavirus DNA prevalence in mature women with negative computer-imaged liquid-based Pap tests. Cancer 2007; 111:292-297.
16. Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001; 285:2995-3002.
17. Bouvard V, Baan R, Straif K, et al. A review of human carcinogens. B. Biological agents. Lancet Oncol 2009; 10:321-322.
18. Maucort-Boulch D, Franceschi S, Plummer M; IARC HPV Prevalence Surveys Study Group. International correlation between human papillomavirus prevalence and cervical cancer incidence. Cancer Epidemiol Biomarkers Prev 2008; 17:717-720.
19. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase no. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010. http://globocan.iarc.fr. Accessed 15 June 2010.
20. Wellings K, Collumbien M, Slaymaker E, et al. Sexual behaviour in context: a global perspective. Lancet 2006; 368:1706-1728.
21. Rodriguez AC, Schiffman M, Herrero R, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008; 100:513-517.
22. Franceschi S, Herrero R, Clifford GM, et al. Variations in the agespecific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119:2677-2684.
23. Smith JS, Melendy A, Rana RK, Pimenta JM. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008; 43:S5-S25.
24. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1796-1807.
25. Lazcano-Ponce E, Herrero R, Muñoz N, et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 2001; 91:412-420.
26. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191:1808-1816.
27. Trottier H, Mahmud S, Prado JC, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008; 197:1436-1447.
28. Muñoz N, Hernandez-Suarez G, Mendez F, et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 2009; 100:1184-1190.
29. Muñoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190:2077-2087.
30. Passmore JA, Morroni C, Shapiro S, Williamson AL, Hoffman M. Papanicolaou smears and cervical inflammatory cytokine responses. J Inflamm (Lond) 2007; 4:8.
31. Althoff KN, Paul P, Burke AE, Viscidi R, Sangaramoorthy M, Gravitt PE. Correlates of cervicovaginal human papillomavirus detection in perimenopausal women. J Womens Health (Larchmt) 2009; 18:1341-1346.
32. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26(suppl 10):K1-K16.
33. Sichero L, Ferreira S, Trottier H, et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007; 120:1763-1768.
34. Castellsague X, Klaustermeier J, Carrilho C, et al. Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: burden and potential for prevention. Int J Cancer 2008; 122:1901-1904.
35. Castellsague X, Menendez C, Loscertales MP, et al. Human papillomavirus genotypes in rural Mozambique. Lancet 2001; 358:1429-1430.
36. Snijders PJ, van den Brule AJ, Meijer CJ. The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol 2003; 201:1-6.
37. Gravitt PE, Coutlee F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cervical cancer screening. Vaccine 2008; 26(suppl 10):K42-K52.
38. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999; 37:2508-2517.
39. Qu W, Jiang G, Cruz Y, et al. PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol 1997; 35:1304-1310.
40. World Health Organization. WHO HPV Laboratory Network. http://www.who.int/biologicals/areas/vaccines/hpv-labnet/en/index.html. Accessed 25 November 2009.
41. Kitchener HC, Castle PE, Cox JT. Chapter 7: Achievements and limitations of cervical cytology screening. Vaccine 2006; 24(suppl 3):S63-S70.